CHMP

January 4, 2021January 4, 2021

Conditional Approval Urged in EU for Trastuzumab Deruxtecan

News

The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency, has recommended the conditional approval of trastuzumab deruxtecan (DS-8201) for the treatment of patients with inoperable or metastatic HER2-positive breast ... Read more

July 3, 2019

CHMP Recommends Tecentriq-Abraxane Combination to Treat Some Triple-negative Breast Cancers in Europe

News

The  Committee for Medicinal Products for Human Use (CHMP),  an arm of the  European Medicines Agency , has recommended the approval of Tecentriq (atezolizumab) in combination with the chemotherapy Abraxane (nab-paclitaxel) as a ... Read more

March 20, 2019

CHMP Favors EU Approval of Lynparza for Some Advanced Breast Cancers

News

The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency (EMA), has recommended the approval of Lynparza (olaparib) tablets for the treatment of advanced breast ... Read more